Compare Aurora Cannabis Inc (ACB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aurora Cannabis Inc vs IDEXX Laboratories, Inc. — how do they compare? Aurora Cannabis Inc trades at $2.68 (market cap $165.36M), while IDEXX Laboratories, Inc. trades at $556.39 (market cap $44.98B). The key difference: IDEXX Laboratories, Inc. is far larger — about 272× Aurora Cannabis Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Aurora Cannabis Inc nearer its low. Which is the better fit depends on your goals.
| ACB | IDXX | |
|---|---|---|
Market Cap | $165.36M | $44.98B |
Sector | Health | Health |
52-Week High | $6.23 | $766.68 |
52-Week Low | $2.67 | $514.61 |
Enterprise Value | $99.82M | $45.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.
The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.
IDXX trades at $570.25, up 2.23% today, with strong technical momentum as it approaches resistance near $572. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics. Analyst sentiment is bullish with a $645 consensus target, though elevated valuations pose a risk.
Outlook remains positive given consistent earnings beats and strategic AI integration, but high P/E of 41.57 suggests limited margin for error. Key risks include competitive pressures and reliance on pet healthcare spending cycles. Institutional ownership trends and upcoming Q2 earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
